日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

SHP2 抑制可增强多种致癌基因依赖性实体肿瘤对靶向治疗的再治疗敏感性

Alexander Drilon, Manish R Sharma #, Melissa L Johnson #, Timothy A Yap #, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B Reddy, Allison S Harney, Mohamed Elsayed, Adam W Cook, Christina E Wong, Ronald J Hinklin, Yutong Jiang, Eric N Brown, Nickolas A Neitzel, Ellen R Laird, Wen-I Wu, Anurag Sin

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

一项 2 期开放标签试验 (ATLAS) 评估了 rucaparib 对既往接受过治疗的局部晚期或转移性尿路上皮癌患者的疗效和安全性。

Grivas, P; Loriot, Y; Morales-Barrera, R; Teo, M Y; Zakharia, Y; Feyerabend, S; Vogelzang, N J; Grande, E; Adra, N; Alva, A; Necchi, A; Rodriguez-Vida, A; Gupta, S; Josephs, D H; Srinivas, S; Wride, K; Thomas, D; Simmons, A; Loehr, A; Dusek, R L; Nepert, D; Chowdhury, S